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Abstract: Narcoleptic patients suffer frequently from obesity and type II diabetes. Most 
patients show a deﬁ  cit in the energy balance regulating orexinergic system. Nevertheless, it is 
not known, why narcoleptic patients tend to be obese. We examined 116 narcoleptic patients 
and 80 controls with the structured interview for anorectic and bulimic eating disorders (SIAB) 
to test the hypothesis that typical or atypical eating attacks or eating disorders may be more 
frequent in narcoleptic patients. No difference in the current prevalence of eating disorders 
bulimia nervosa, binge eating disorder, or anorexia nervosa was found, nor was the frequency 
of eating attacks higher in the narcolepsy group. We conclude that present eating disorders and 
eating attacks as deﬁ  ned in DSM IV are not the reason for the observed differences in body 
composition. Additional factors, such as basal metabolic rates and lifestyle factors need to be 
considered.
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Introduction
Narcolepsy is characterized by the core symptoms: excessive day time sleepiness, 
cataplexies, hypnopompic and hypnagogic hallucinations, sleep paralysis, and phases 
of automatic behavior. It was recently discovered that narcoleptic dogs have a defec-
tive receptor for the peptide orexin (Lin et al 1999) and that orexin knock out mice 
display behavioral anomalies reminiscent to human narcolepsy (Chemelli et al 1999). 
Investigations into the orexinergic system in humans revealed that most narcoleptics 
with cataplexies show diminished levels of orexin in the cerebrospinal ﬂ  uid (CSF), 
typically below the detection limit of commercially available antibodies, whereas 
healthy controls show orexin levels above 200 pg/ml (Dauvilliers et al 2003). Orexin 
(hypocretin) is involved in various aspects of energy homeostasis. It stimulates feeding 
behavior and, in many neurons, counteracts the effects of the satiety hormone leptin 
(Baumann et al 2005). In addition, Orexin promotes vigilance and attention.
Narcolepsy is tightly associated with the human leukocyte antigen (HLA) system. 
More than 90% of the patients are positive for HLA DR2 and it is mostly the HLA 
DR2 patients who lack orexin in the CSF. The lack of orexin is thought to be due to a 
speciﬁ  c degeneration of orexinergic neurons located in the hypothalamus. The degen-
erative process is probably autoimmunological in nature (Black 2005). Nevertheless, 
the causes for narcolepsy remain poorly understood.
Narcoleptic patients exhibit a marked increase of body weight. In German popula-
tions, narcoleptics had 3–4 body mass index (BMI) points more than control popula-
tions and the national average (Schuld et al 2000; Dahmen et al 2001, Nishino et al 
2001; Kok et al 2003). Patients anecdotally give testimony of increased appetite and 
altered food preferences that occur around the time of narcolepsy symptom onset. 
However, the issue of comorbidity with eating disorders or subsyndromal eating 
anomalies has never been formally studied. Peyron and colleagues (2000) described Neuropsychiatric Disease and Treatment 2008:4(1) 258
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a juvenile narcoleptic patient with a rare genetic defect in the 
orexin system, who was additionally suffering from bulimic 
eating attacks.
We investigated 116 narcoleptic patients, 80 unrelated 
healthy controls with the self-report version (SIAB-S) of the 
structured interview for anorectic and bulimic eating disor-
ders (SIAB) devised by Fichter and Quadﬂ  ieg (2001). The 
study is part of a broader effort to characterize narcoleptic 
patients clinically, genetically, and biochemically.
Methods
Patients
Patients were recruited with the help of the German Narco-
lepsy Association (Deutsche Narkolepsie Gesellschaft), a 
nationwide self-help group that promotes the exchange of 
information between affected members and whose members 
have been participated in many scientiﬁ  c studies in narco-
lepsy. The diagnosis of narcolepsy was based on the unam-
biguous presence of cataplexies (95%) and severe day-time 
sleepiness (100%). Patients without cataplexies were only 
admitted when other rapid eye movement (REM)-associated 
symptoms and results of polysomnographic investigations 
were demonstrating the diagnosis. Most patients exhibited 
additional symptoms such as automatic behavior, hallucina-
tions, and sleep paralysis. The Stanford Centre for Narco-
lepsy Sleep Inventory was used to quantify symptoms. The 
Stanford Centre for Narcolepsy Sleep Inventory consists of 
146 questions organized in eight sections that assess all typi-
cal symptoms of narcolepsy patients. Sections one and two 
collect general and sociodemographic information. Section 
three is the Epworth Sleepiness Scale (ESS). Section four 
asks for sleep quality and medication. Sections ﬁ  ve, six, 
seven, and eight are concerned with cataplexies, hallucina-
tions, sleep paralysis, and automatic behavior, respectively. 
The core section on cataplexies section has been validated in 
983 sleep-disorders patients (Anic-Labat et al 1999). Patients 
were investigated in respect to HLA status as described by 
Olerup and Zetterquist (1992). Patients and controls are 
depicted in Table 1
Controls
Controls were recruited by advertisements and postings 
within the local community. All controls were free of narco-
lepsy symptoms. Neither controls nor patients were suffering 
from acute psychiatric disorders such as acute depression that 
could inﬂ  uence eating behavior or food choice (Harris et al 
1986; Pijl et al 1994). All participants gave informed consent. 
The study was approved by the local ethics committee.
SIAB-S-Questionnaire
The SIAB-S Questionnaire consists of 81 items and is 
speciﬁ  cally designed to assess pathological eating patterns as 
well as related symptoms such as depressed mood, impaired 
social integration, and dysfunctional self images and body 
perceptions. In contrast to most other eating questionnaires, 
the SIAB-S allows also for a diagnostic evaluation according 
to ICD10 and DSM IV since 20 of the items are formulated 
in a way to assess diagnostic criteria. Since its inception, the 
SIAB has been validated in several clinical populations and 
in addition in a number of scientiﬁ  c studies, among which 
are several large multicenter studies into the genetics of 
eating disorders.
In addition the SIAB allows to deﬁ  ne subsyndromal cat-
egories. Bulimia nervosa binge was deﬁ  ned as binge-eating 
disorder without DSM IV criterion C (more than two eating 
attacks per week). Bulimic syndrome was deﬁ  ned as bulimia 
nervosa with eating attacks (criterion A) and either recur-
rent inappropriate compensatory behavior or a frequency 
of at least twice weekly (criteria B or C) but without undue 
inﬂ  uence of self-evaluation (criterion D). Atypical bulimic 
behavior is characterized by the steady consumption of sweet 
or otherwise high caloric food throughout the day.
The anorectic syndrome was deﬁ  ned as refusal to main-
tain body weight above minimal normal weight (criterion A) 
and either intense fear of gaining weight or disturbance in 
the way in which the body weight or shape is experienced 
(criteria B or C).
Regular (inappropiate) compensatory behavior is the dis-
proportionate and undue effort to counteract food intake either 
Table 1 Characteristics of patients and controls
 Narcoleptics  Controls
Number (n)
All 116  80
Females  81 (69.8%)  44 (55%)
Males  35 (30.2%)  36 (45%)  0.0359
Age (years)
All 50.7  ± 16.0  40.8 ± 15.2   0.0001
Females 47.9  ± 16.7  45.4 ± 15.7  ns
Males 57.3  ± 12.2  35.1 ± 12.5   0.0001
BMI
All 28.3  ± 5.5  25.1 ± 5.3   0.0001
Females 28.2  ± 6.1  25.0 ± 5.4  0.0042
Males 28.6  ± 4.0  25.2 ± 5.3  0.0033
Age of onset 22.4  ± 10.7  na
Epworth sleepiness scale 18.4  ± 4.5  na
HLA DR2 (n = 92)  86 (93%)  na
Abbreviations: BMI, body mass index; HLA, human leukocyte antigen; na, not 
available; ns, not signiﬁ  cant.Neuropsychiatric Disease and Treatment 2008:4(1) 259
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through laxative medication, diuretics, or excessive sport. 
Spitting is chewing and spitting of foodstuff without swallow-
ing. Regurgitation is self-induced vomiting after eating.
Patients and controls ﬁ  lled out the questionnaires after the 
diagnosis was checked by an experienced physician (ND). 
All participants had additional opportunities to ask questions 
concerning the correct interpretation of questions. To assure 
data quality, questionnaires were reviewed in the presence 
of participants and gaps were ﬁ  lled.
Primary outcome parameters were the frequencies of 
typical and atypical eating attacks as well as eating disorder 
diagnoses.
Statistics
All statistical calculations were done with the help of a com-
mercial statistics package (SPSS). Exploratory statistics and, 
where appropriate, the comparison of mean values (t-tests) 
and distributions (Chi-square tests) were calculated. No cor-
rections were made for multiple testing, because we sought 
to increase the likelihood to generate hypotheses, rather then 
to conﬁ  rm pre-established relations.
Results
No difference in the present prevalences of DSM IV eat-
ing disorders bulimia disorder, binge-eating disorder, and 
anorexia nervosa was found. As with the formal eating dis-
orders, none of the subsyndromal categories was signiﬁ  cantly 
different between narcoleptics and controls (Table 2)
Next, we assessed the frequency of eating attacks without 
regard to speciﬁ  c diagnoses (Table 3). Again, no difference 
was apparent between narcoleptics and controls.
Finally, we were interested in the effect of hyperphagic 
behavior on the actual BMI. Persons with hyperphagic traits 
(any hyperphagic diagnosis, see Table 2) have a higher BMI 
(narcoleptics: 30.3 ± 6.3; controls: 27.7 ± 5.8) than persons 
without (narcoleptics: 28.0 ± 5.4; controls: 25.4 ± 4.7), 
regardless of the narcolepsy diagnosis.
Discussion
The ﬁ  rst result of this study was that eating disorders as 
deﬁ  ned in DSM and ICD 10 were not more prevalent in 
narcoleptic patients than in controls. Disorders associated 
with hyperphagic behavior (bulimia nervosa, binge-eating 
disorder, and the subsyndromal entities bulimic syndrome, 
atypical bulimia and bulimia nervosa “binge”) were of par-
ticular interest, because narcoleptic patients generally show 
increased BMIs. In addition, no differences between narco-
leptic patients and controls were noted for the frequency of 
typical and atypical eating attacks. Hyperphagic behavior, 
when present, was associated with an increase in BMI for 
both narcoleptics and controls.
Taken together, the results indicate that overt anomalies 
in eating behavior are not the reason for the higher BMI of 
narcoleptic patients and that other mechanisms need to be 
explored. The narcoleptic sample consisted of slightly more 
women than the control sample. One could argue that both 
samples are not perfectly matched and thus not comparable. 
However, eating disorders are more frequent in women, than 
in men. Therefore, the study group composition was, if at 
all, biased towards a higher incidence of eating anomalies 
in the narcolepsy group that still was not detectable. In addi-
tion, the age of the men in the control sample was younger 
Table 2 Frequencies of current eating disorders in narcoleptic patients and controls: no signiﬁ  cant differences were detected 
(Chi-square tests)
Disorder Narcoleptic  [Male/Female]  Controls  [Male/Female]
Hyperphag
Any hyperphag diagnosis  15 (13%)  [6/9]  14 (18%)  [7/7]
Bulimia nervosa  2 (2%)  [0/2]  0 (0%)  [0/0]
Binge eating disorder  3 (3%)  [1/2]  1 (1%)  [0/1]
Bulimia nervosa binge  6 (5%)  [3/3]  1 (1%)  [0/1]
Bulimic syndrome  10 (9%)  [5/5]  11 (14%)  [4/7]
Atypical bulimic  8 (7%)  [3/5]  7 (9%)  [5/2]
Hypophag
Anorexia nervosa  0 (0%)  [0/0]  0 (0%)  [0/0]
Anorectic syndrome  0 (0%)  [0/0]  0 (0%)  [0/0]
Other
Regular compensatory  9 (8%)  [1/8]  2 (3%)  [0/2]
Spitting  0 (0%)  [0/0]  0 (0%)  [0/0]
Regurgitation  0 (0%)  [0/0]  0 (0%)  [0/0]Neuropsychiatric Disease and Treatment 2008:4(1) 260
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than in the narcoleptic sample, possibly reﬂ  ecting the lower 
inclination of older male controles to detail on eating habits. 
Medications such as antidepressants or stimulants can stimu-
late (eg, tricyclics) or suppress (eg, stimulants) appetite and 
thus modify eating behavior. However, as we have shown 
in a previous paper, narcolepsy medication status had no 
demonstrable association with the BMI of obese narcoleptics 
(Dahmen et al 2001). All prevalences are well within the 
range commonly reported for eating disorders in Western 
countries (Hoek and Hoeken 2003; Makino et al 2004).
A clear limitation of the study is that the SIAB ques-
tionnaire is suited only to detect rather gross anomalies of 
feeding behavior. Discrete changes in food preference or 
eating habits could be physiologically relevant but unde-
tectable within our study design. It is well known that 
rather small imbalances in energy homoeostasis can, over 
time, lead to remarkable changes in body shape. Moreover, 
we investigated only symptoms that were present during 
the time of interview (last three months). Thus it can not 
be ruled out that eating disorders or eating anomalies might 
manifest at some point in the life of narcoleptic patients, 
eg, at the time of onset and then ameliorate or disappear. 
In addition, the (parasomnic) sleep related eating disorder 
(Schenck et al 1991) and the night eating syndrome are not 
covered by the SIAB, so that the potential contribution to 
increased BMIs of these disorders could not be evaluated. 
Both traits are not known to be necessarily associated with 
obesity or increased BMIs in general (Schenck et al 1993; 
Striegel-Moore et al 2006) but may play a role in subsets 
of obese persons or under speciﬁ  c circumstances such as 
in narcolepsy.
There are no data in the literature in respect to meta-
bolic basal or resting rates of narcoleptic patients. Orexin 
neuron-deﬁ  cient transgenic mice, however, have been 
reported to show lower rates of basal metabolism and also 
to display higher body weight, when caged under identical 
conditions, than control animals (Hara et al 2005). Another 
reason for narcoleptic patients to be more obese may be 
found in the lifestyle usually associated with narcolepsy. 
Patients tend to be less active in sports and other activities 
and thus could be prone to obesity because of a imbalance 
between “normal” calorie intake and reduced consumption 
after the onset of symptoms. In line with this suggestion, 
Pollak and Green (1990) showed that the degree of “post-
prandial deactivation” was much larger in narcoleptics 
than in controls.
The relation between reduced or absence of orexin and 
increase of body weight is a complex one, because typically 
reduced orexin would be expected to lead to a reduction of 
food intake and hence to a lower, not higher body weight. 
In fact, in a study of 12 narcoleptic patients, Lammers and 
colleagues (1996) showed that the caloric intake and particu-
larly the carbohydrate intake were reduced in comparison 
to controls.
One of the additional factors worth to be considered 
might be the leptin-signaling system. Leptin levels have 
been reported to be reduced in narcoleptic patients (Schuld 
et al 2000; Kok et al 2002). Because leptin is produced by 
fat cells as part of a signaling pathway to maintain long 
term energy balance, the incapacitation of this signaling 
could indeed contribute to a positive energy balance. 
However, newer reports have not replicated the ﬁ  nding 
of lowered leptin levels (Arnulf et al 2006; Dahmen et al 
2007).
Conclusion
Narcoleptic patients do not show increased prevalences of 
eating disorders and present eating symptomatology may not 
explain the increased BMI of narcoleptic patients. Therefore 
studies covering past symptoms and studies with more precise 
instruments, including those measuring satiety after stan-
dardized meals and assessing sleep-related eating disorders 
seem worthwhile. In addition the attempt to measure basal 
metabolic rates in narcoleptic patients by indirect calorimetry 
may be a way to gain additional insights.
Table 3 Frequency of current eating attacks in narcoleptic 
patients and controls: no signiﬁ  cant differences were detected 
(Chi-sqare tests)
Frequency of eating attacks  Narcoleptics  Controls
All (n = 114 + 80)
Never  88 (77%)  63 (79%)
 1–4x/month  11 (10%)  12 (15%)
 2x/week  4 (4%)  4 (5%)
 1x/day  7 (6%)  1 (1%)
 1x/day  4 (4%)  0 (0%)
Women (n = 80 + 44)
Never  61 (76%)  36 (82%)
1–4x/month  8 (10%)  3 (7%)
 2x/week  2 (3%)  4 (9%)
 1x/day  6 (8%)  0 (0%)
 1x/day  3 (4%)  1 (2%)
Men (n = 34 + 36)
Never  27 (79%)  27 (75%)
1–4x/month  3 (9%)  9 (25%)
 2x/week  2 (6%)  0 (0%)
 1x/day  1 (3%)  0 (0%)
 1x/day  1 (3%)  0 (0%)Neuropsychiatric Disease and Treatment 2008:4(1) 261
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